Sterling Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Sterling Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.38K	Sell	1,196 -653	-35%	-$3.97K	﹤0.01%	2692
2026 Q1	$14.2K	Sell	1,849 -483	-21%	-$4.48K	﹤0.01%	2188
2025 Q4	$26.4K	Sell	2,332 -414	-15%	-$4.21K	﹤0.01%	2081
2025 Q3	$25.3K	Buy	2,746 +1,407	+105%	+$10.2K	﹤0.01%	2029
2025 Q2	$9.21K	Buy	1,339 +778	+139%	+$4.16K	﹤0.01%	2176
2025 Q1	$1.62K	Sell	561 -678	-55%	-$2.49K	﹤0.01%	2669
2024 Q4	$5.82K	Buy	1,239 +1,099	+785%	+$4.05K	﹤0.01%	2392
2024 Q3	$500	Buy	+140	New	+$1.04K	﹤0.01%	2870

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sterling Capital Management's FULC Position: Q2 2026 in Review

Sterling Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 35% in Q2 2026, selling an estimated $3.97K and leaving 1,196 shares worth $4.38K. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

Sterling Capital Management first reported a position in FULC in Q3 2024 and has held it in 8 quarters since. The position peaked at $26.4K in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Sterling Capital Management held 1,196 shares of Fulcrum Therapeutics worth $4.38K as of Q2 2026.
Sterling Capital Management sold 653 Fulcrum Therapeutics shares in Q2 2026, an estimated $3.97K.
Fulcrum Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2692 holding.
Sterling Capital Management first reported a position in Fulcrum Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Fulcrum Therapeutics position peaked at $26.4K in Q4 2025.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.